Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Visuoperception Test Predicts Pathologic Diagnosis of Alzheimer Disease in Corticobasal Syndrome
Neurol 83:510-519, Boyd, C.D.,et al, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
TREM2 Variants in Alzheimers Disease
NEJM 368:117-127, Guerreiro, R.,et al, 2013
Variant of TREM2 Associated with the Risk of Alzheimers Disease
NEJM 368:107-116, Jonsson, T.,et al, 2013
Variant TREM2 as Risk Factor for Alzheimers Disease
NEJM 368:182-184, Neumann, H. & Daly, M., 2013
Memory Enhancement and Deep-Brain Stimulation of the Entorhinal Area
NEJM 366:502-510, Suthana,N.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Alzheimers Disease
NEJM 362:329-344, Querfurth,H.W. &LaFerla,F.M., 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Genetic Factors in Alzheimer's Disease
NEJM 352: 862-863, 884, Bird, T., 2005
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -Yes
Neurol 55:740-742, Forbes,W.F.&Hill,G.B., 1998
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -No
Arch Neurol 55:737-739, 7421998., Munoz,D.G., 1998
Smoking and Risk of Dementia and Alzheimer's Disease in a Population-Based Cohort Study:The Rotterdam Study
lancet 351:1840-1843, Ott,A.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
JAMA 277:825-831, Lendon,C.L.,et al, 1997
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Incorrect Diagnosis of Alzheimer's Disease:A Clinicopathologic Study
Arch Neurol 53:35-42, Klatka,L.A.,et al, 1996
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Elevated Risk of Alzheimer's Disease Among Workers with Likely Electromagnetic Field Exposure
Neurol 47:1477-1481, Sobel,E.,et al, 1996
Electromagnetic Field Exposure May Cause Increased Production of Amyloid Beta & Eventually lead to Alzheimer's Disease
Neurol 47:1594-1600, Sobel,E.&Davanipour,Z., 1996
Image Analysis of B-Amyloid Load in Alzheimer's Disease and Relation to Dementia Severity
Lancet 346:1524-1528, Cummings,B.J.&Cotman,C.W., 1995
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Apolipoprotein E Polymorphism and Alzheimer's Disease
Lancet 342:697-699, 6961993., Poirier,J.,et al, 1993
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
The Molecular Pathogenesis of Alzheimer's Disease:Clinical Prospects
Lancet 340:1512-1515, Murphy,M., 1992
Clinical and Pathological Aspects of Parkinsonism in Alzheimer's Disease, A Role for Extranigral Factors?
Arch Neurol 46:651-657, Morris,J.C.,et al, 1989
Induction of Parkinsonism by Intraventricular Bethanechol in a Patient with Alzheimer's Disease
Neurol 39:1265, Fox,J.H.,et al, 1989
Olfactory Dysfunction in Parkinsonism:A General Deficit Unrelated to Neurologic Signs, Disease Stage, or Duration
Neurol 38:1237-1244, Doty,R.L.,et al, 1988
Neuropathologic & Clinical Features of Parkinson's Disease in Alzheimer's Disease Patients
Neurol 37:754-760, Ditter,S.M.&Mirra,S.S., 1987
Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986
Parkinson's Disease in Patients with Alzheimer's Disease
Arch Neurol 43:662-664, Leverenz,J.&Sumi,S.M., 1986
Alzheimer's Disease, Parkinson's Disease, & Motoneurone Disease:Abiotropic Interaction Between Ageing & Environment
Lancet 2:1067-1068, Calne,D.B.,et al, 1986
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986